Substance for obtaining highly effective tumor medications as well as a process

Abstract

The invention relates to a substance and a process for obtaining anti-tumor agents.

1 . Glycoprotein that comprises at least one section of the amino acid primary structure of CD55 and a tumor-specific glycostructure. 
     
     
         2 . Glycoprotein according to  claim 1 , characterized in that the glycostructure reacts with monoclonal antibody SC-1. 
     
     
         3 . Glycoprotein according to  claim 1  or  2 , wherein in SDS-polyacrylamide-gel electrophoresis, it exhibits an apparent molecular weight of 82 kD. 
     
     
         4 . Process for obtaining a glycoprotein according to one of  claims 1  to  3 , wherein membrane preparations are produced from cells of the human adenocarcinoma cell line 23132, and the glycoprotein is obtained therefrom by size-exclusion and/or anion-exchange chromatography. 
     
     
         5 . Use of a glycoprotein according to one of  claims 1  to  3  in a test process in which the ability of a substance to bind to the glycoprotein is determined. 
     
     
         6 . Use according to  claim 5 , wherein the ability to bind to the glycostructure is determined. 
     
     
         7 . Use according to  claim 5  or  6 , wherein the ability of the tested substance to induce apoptosis, especially in tumor cells, is determined. 
     
     
         8 . Use according to one of  claims 5  to  7 , wherein the ability of the tested substance to induce a phosphorylation cascade that is mediated by glycoprotein CD55 is determined. 
     
     
         9 . Use according to  claims 5  to  8 , wherein the glycoprotein is used in isolated form, as a cell extract, especially as a membrane preparation or in the form of complete cells, especially of human adenocarcinoma cell line 23132. 
     
     
         10 . Use according to one of  claims 5  to  9  for identifying substances that bind specifically to tumor cells. 
     
     
         11 . Use according to  claim 10  for identifying agents for tumor diagnosis and/or tumor therapy. 
     
     
         12 . Use according to one of  claims 5  to  11 , wherein the pharmacologically compatible substances are tested. 
     
     
         13 . Use according to  claim 12 , wherein the tested substances are selected from peptides, peptide mimetic agents, antibodies, antibody fragments and antibody derivatives. 
     
     
         14 . Use of substances that bind specifically to a glycoprotein according to one of  claims 1  to  3 , with the exception of the monoclonal antibody SC-1, for the production of agents that induce apoptosis. 
     
     
         15 . Use of substances that bind specifically to a glycoprotein according to one of  claims 1  to  3 , with the exception of monoclonal antibody SC-1, for the production of anti-tumor agents. 
     
     
         16 . Use of substances that bind specifically to a glycoprotein according to one of  claims 1  to  3 , with the exception of monoclonal antibody SC-1, for the production of agents for tumor diagnosis. 
     
     
         17 . Process for the preparation of the agents that induce apoptosis, wherein a potentially active substance is tested on its ability for specific binding to a glycoprotein according to one of  claims 1  to  3  and in the case of a positive test result, the substance is converted into a form for dispensing that is suitable for pharmaceutical applications optionally together with commonly used adjuvants, additives and vehicles. 
     
     
         18 . Process for the preparation of anti-tumor agents, wherein a potentially active substance is tested on its ability for specific binding to a glycoprotein according to one of  claims 1  to  3  and in the case of a positive test result, the substance is converted into a form for dispensing that is suitable for pharmaceutical applications optionally together with commonly used adjuvants, additives and vehicles. 
     
     
         19 . Process for combatting tumors, wherein an anti-tumor-action quantity of a substance that can bind specifically to a glycoprotein according to one of  claims 1  to  3 , with the exception of monoclonal antibody SC-1, is administered to a patient. 
     
     
         20 . Process for diagnosis of tumors, wherein a sample that is to be tested or a patient who is to be tested is brought into contact with a substance that can bind specifically to a glycoprotein according to one of  claims 1  to  3 , and the presence, the localization and/or the quantity of the glycoprotein in the sample or in the patient is detected. 
     
     
         21 . Use of substances that specifically bind a glycoprotein according to one of  claims 1  to  3  to trigger a phosphorylation cascade in tumor cells. 
     
     
         22 . Use of substances that bind specifically to a glycoprotein according to one of  claims 1  to  3  for transient increase of the CD55/DAF presentation in membranes of tumor cells. 
     
     
         23 . Use of substances that specifically bind a glycoprotein according to one of  claims 1  to  3  for inducing apoptotic processes that do not comprise any cleavage of poly(ADP-ribose)-polymerase (PARP). 
     
     
         24 . Use of substances that specifically bind a glycoprotein according to one of  claims 1  to  3  for inducing a cell cycle arrest in tumor cells. 
     
     
         25 . Use of substances that bind specifically to a glycoprotein according to one of  claims 1  to  3  for inducing apoptosis in dormant tumor cells. 
     
     
         26 . Use according to one of  claims 21  to  25 , wherein the specifically bindable substance comprises antibody SC-1. 
     
     
         27 . Use according to one of  claims 21  to  26 , wherein the substances are used in the form of conjugates with labeling or effector groups. 
     
     
         28 . Use according to one of  claims 21  to  27 , wherein the substances have multiple binding sites for a glycoprotein according to one of  claims 1  to  3 . 
     
     
         29 . Use according to  claim 28 , wherein the specifically bindable substances are cross-linked.